Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Similar articles for PubMed (Select 23218213)

1.

A welfare economic approach to measure outcomes in stuttering: comparing willingness to pay and quality adjusted life years.

Franic DM, Bothe AK, Bramlett RE.

J Fluency Disord. 2012 Dec;37(4):300-13. doi: 10.1016/j.jfludis.2012.04.005. Epub 2012 May 10.

PMID:
23218213
2.

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA.

Pharmacoeconomics. 2009;27(12):1005-16. doi: 10.2165/11314000-000000000-00000.

PMID:
19908925
3.

Assessment of respondent acceptability for preference measures in stuttering.

Franic DM, Bothe AK, Bramlett RE.

J Commun Disord. 2012 Sep-Oct;45(5):378-89. doi: 10.1016/j.jcomdis.2012.05.001. Epub 2012 May 18.

PMID:
22682377
4.
5.

Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.

King JT Jr, Tsevat J, Lave JR, Roberts MS.

Med Decis Making. 2005 Nov-Dec;25(6):667-77.

PMID:
16282217
6.

Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.

Byrne MM, O'malley K, Suarez-Almazor ME.

Med Decis Making. 2005 Nov-Dec;25(6):655-66.

PMID:
16282216
7.

Willingness to pay for a QALY: theoretical and methodological issues.

Gyrd-Hansen D.

Pharmacoeconomics. 2005;23(5):423-32. Review.

PMID:
15896094
8.

Willingness to pay and time trade-off: sensitive to changes of quality of life in psoriasis patients?

Schiffner R, Schiffner-Rohe J, Gerstenhauer M, Hofstädter F, Landthaler M, Stolz W.

Br J Dermatol. 2003 Jun;148(6):1153-60.

PMID:
12828743
9.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

10.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

11.

Estimating a WTP-based value of a QALY: the 'chained' approach.

Robinson A, Gyrd-Hansen D, Bacon P, Baker R, Pennington M, Donaldson C; EuroVaQ Team.

Soc Sci Med. 2013 Sep;92:92-104. doi: 10.1016/j.socscimed.2013.05.013. Epub 2013 Jun 4.

PMID:
23849283
12.

Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.

Baker R, Bateman I, Donaldson C, Jones-Lee M, Lancsar E, Loomes G, Mason H, Odejar M, Pinto Prades JL, Robinson A, Ryan M, Shackley P, Smith R, Sugden R, Wildman J; SVQ Research Team.

Health Technol Assess. 2010 May;14(27):1-162. doi: 10.3310/hta14270.

13.

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators.

Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260.

14.

Willingness to pay: a valid and reliable measure of health state preference?

O'Brien B, Viramontes JL.

Med Decis Making. 1994 Jul-Sep;14(3):289-97.

PMID:
7934716
16.
17.

Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.

Lee GM, Salomon JA, Gay C, Hammitt JK.

Health Qual Life Outcomes. 2010 Mar 12;8:28. doi: 10.1186/1477-7525-8-28.

18.
19.

Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years.

Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B.

J Clin Epidemiol. 1998 Aug;51(8):667-76.

PMID:
9743315
20.

Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma.

Blumenschein K, Johannesson M.

Ann Allergy Asthma Immunol. 1998 Feb;80(2):189-94.

PMID:
9494453
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk